REVIEW OF PLACEBO-CONTROLLED TRIALS WITH BUPROPION

Abstract

Results of 4 multicenter randomized double-blind placebo-controlled studies of the antidepressant efficacy and safety of bupropion are reviewed. Bupropion was superior to placebo on the Hamilton Depression and Anxiety Rating Scales, Clinical Global Impressions-Improvement, and patient self-rating scales [Zung Self-Rating Depression Scale and Zung Self-Rating Anxiety Scale]. The proportion of patients responding to bupropion was typically 60-70% vs. .apprx. 30% for placebo. Drug-placebo differences became apparent at 5 days to 3 wk after treatment initiation. With respect to subjective side effects, bupropion exhibited a profile very similar to that of placebo. No clinical significant cardiovascular or clinical laboratory changes were noted. Bupropion appears to be an effective broad-spectrum antidepressant with an excellent side effect profile.